# HLA-G (6D463): sc-71263



The Power to Question

## **BACKGROUND**

Major histocompatibility complex (MHC, human leukocyte antigen (HLA) molecules are cell-surface receptors that bind foreign peptides and present them to T lymphocytes. MHC class I molecules consist of two polypeptide chains, an  $\alpha$  or heavy chain, and a non-covalently associated protein,  $\beta$ -2-Microglobulin. Cytotoxic T lymphocytes bind antigenic peptides presented by MHC class I molecules. Antigens that bind to MHC class I molecules are typically 8-10 residues in length and are stabilized in a peptide binding groove. MHC class II molecules are encoded by polymorphic MHC genes and consist of a non-covalent complex of an  $\alpha$  and  $\beta$  chain. Helper T lymphocytes bind antigenic peptides presented by MHC class II molecules. MHC class II molecules bind 13-18 amino acid antigenic peptides. Accumulating in endosomal/lysosomal compartments and on the surface of B cells, HLA-DM and -DO molecules regulate binding of exogenous peptides to class II molecules (HLA-DR) by sustaining a conformation that favors peptide exchange. The differential structural properties of MHC class I and class II molecules account for their respective roles in activating different populations of T lymphocytes.

## **REFERENCES**

- Fournel, S., et al. 2000. Comparative reactivity of different HLA-G monoclonal antibodies to soluble HLA-G molecules. Tissue Antigens 55: 510-518.
- 2. Lozano, J.M., et al. 2002. Monocytes and T lymphocytes in HIV-1-positive patients express HLA-G molecule. AIDS 16: 347-351.
- 3. Pangault, C., et al. 2002. Lung macrophages and dendritic cells express HLA-G molecules in pulmonary diseases. Hum. Immunol. 63: 83-90.
- 4. Fuzzi, B., et al. 2002. HLA-G expression in early embryos is a fundamental prerequisite for the obtainment of pregnancy. Eur. J. Immunol. 32: 311-315.
- 5. Boyson, J.E., et al. 2002. Disulfide bond-mediated dimerization of HLA-G on the cell surface. Proc. Natl. Acad. Sci. USA 99: 16180-16185.
- Menier, C., et al. 2003. Characterization of monoclonal antibodies recognizing HLA-G or HLA-E: new tools to analyze the expression of nonclassical HLA class I molecules. Hum. Immunol. 64: 315-326.

#### **CHROMOSOMAL LOCATION**

Genetic locus: HLA-G (human) mapping to 6p22.1.

# **SOURCE**

HLA-G (6D463) is a mouse monoclonal antibody raised against recombinant HLA-G denatured heavy chain of human origin.

#### **PRODUCT**

Each vial contains 100  $\mu g \ lg G_1$  in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

# **STORAGE**

Store at 4° C, \*\*DO NOT FREEZE\*\*. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

# **APPLICATIONS**


HLA-G (6D463) is recommended for detection of denatured HLA-G heavy chain of human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and immunohistochemistry (including paraffinembedded sections) (starting dilution 1:50, dilution range 1:50-1:500).

Suitable for use as control antibody for HLA-G siRNA (h): sc-42920, HLA-G shRNA Plasmid (h): sc-42920-SH and HLA-G shRNA (h) Lentiviral Particles: sc-42920-V.

Molecular Weight of HLA-G: 39 kDa.

Positive Controls: K-562 whole cell lysate: sc-2203, Jurkat whole cell lysate: sc-2204 or HLA-G (h): 293T Lysate: sc-159408.

# **DATA**



HLA-G (6D463): sc-71263. Western blot analysis of HLA-G expression in non-transfected: sc-117752 (A) and human HLA-G transfected: sc-159408 (B) 293T whole rell lysates

# **RESEARCH USE**

For research use only, not for use in diagnostic procedures.

# **PROTOCOLS**

See our web site at www.scbt.com for detailed protocols and support products.



See **HLA-G** (4H84): sc-21799 for HLA-G antibody conjugates, including AC, HRP, FITC, PE, and Alexa Fluor\* 488, 546, 594, 647, 680 and 790.

Santa Cruz Biotechnology, Inc. 1.800.457.3801 831.457.3800 fax 831.457.3801 Europe +00800 4573 8000 49 6221 4503 0 www.scbt.com